ArticleeLife2021
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant.
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 41 citations in OpenAlex.
- Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.Nature microbiology · 2021Trial
- Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.Blood cancer journal · 2021Trial
- Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine.The veterinary quarterly · 2025Article
- Article
- Validation of dried blood spot sampling for detecting SARS-CoV-2 antibodies and total immunoglobulins in a large cohort of asymptomatic young adults.Journal of immunological methods · 2023Article
- Targeting the hallmarks of aging to improve influenza vaccine responses in older adults.Immunity & ageing : I & A · 2023Review
- Assessing the Impact of Vaccination on the Dynamics of COVID-19 in Africa: A Mathematical Modeling Study.Vaccines · 2023Article
- Article
- Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod.Revue neurologique · 2023Article
- Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals.Communications biology · 2023Article
- Article
- Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals.Research square · 2022Article
- Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey.Scientific reports · 2022Observational
- Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses.Archives of medical research · 2022Article
- Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people.Cell reports. Medicine · 2022Article
- Article
- Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2.Nature microbiology · 2022Article
- Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers.Clinical and experimental immunology · 2022Article
- Covid-19 vaccines and variants of concern: A review.Reviews in medical virology · 2022Review
- Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 2 institutions in 2 countries.
Funding
Abstract
Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However, vaccine responses are often suboptimal in this age group and few people over the age of 80 years were included in vaccine registration trials. We determined the serological and cellular response to spike protein in 100 people aged 80-96 years at 2 weeks after the second vaccination with the Pfizer BNT162b2 mRNA vaccine. Antibody responses were seen in every donor with high titers in 98%. Spike-specific cellular immune responses were detectable in only 63% and correlated with humoral response. Previous SARS-CoV-2 infection substantially increased antibody responses after one vaccine and antibody and cellular responses remained 28-fold and 3-fold higher, respectively, after dual vaccination. Post-vaccine sera mediated strong neutralization of live Victoria infection and although neutralization titers were reduced 14-fold against the P.1 variant first discovered in Brazil they remained largely effective. These data demonstrate that the mRNA vaccine platform delivers strong humoral immunity in people up to 96 years of age and retains broad efficacy against the P.1 variant of concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.